Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/917


Strategic Perspectives 2001: Narcolepsy - Specific Drugs are Waking up the Market


Description: Whilst narcolepsy is not a prevalent disorder, the recentsuccess of the first narcolepsy specific drug, Provigil(modafinil) has created interest in this previously neglectedmarket. With its superior efficacy and safety profilecompared to the previous gold standard treatment, theCNS stimulants, Provigil is expected to continue itssuccess for the foreseeable future.However, Provigil is only effective at treating one of thesymptoms of narcolepsy, excessive daytime sleepiness,and does not treat another commonly experiencedsymptom, cataplexy. Another narcolepsy specific drug,Xyrem (sodium oxybate), which is likely to be availablesoon, seems set to fill this unmet need and become verysuccessful in the future.


Contents: DATAMONITOR HEALTHCARE


CONTACT DETAILS



EXECUTIVE SUMMARY


Scope


Datamonitor insight into the narcolepsy market



Provigil has established itself as the leading drug in the narcolepsy market remarkably rapidly. This is due to its proven efficacy in treating daytime sleepiness and its improved side effect profile and reduced abuse potential compared to the older treatments.


Xyrem (sodium oxybate) is expected to achieve similar success to modafinil when it is approved for treating cataplexy related to narcolepsy. Since Xyrem and modafinil will initially be indicated for different symptoms of narcolepsy, they are unlikely to be in direct competition at first.


Despite the strength of Provigil and Xyrem, there are some unmet needs in the treatment of narcolepsy which may provide opportunities for new drugs to enter the market in the future.



Summary



Key metrics


TABLE OF CONTENTS


NARCOLEPSY OVERVIEW


Etiology


Symptomology


Causes


Epidemiology


Prevalence


Diagnosis and treatment rates


Summary


Diagnosis of narcolepsy



Diagnostic criteria


Treatment


Treatment aims


Treatment guidelines


NARCOLEPSY MARKET ANALYSIS


Narcolepsy drug profiles


Provigil (modafinil)


CNS stimulants


Pemoline


Selegiline


Antidepressants


US market


Assumptions and sources


Compliance rates


Cost of treatment


Market breakdown


European market


Assumptions and sources


Compliance rates


Cost of treatment



Market breakdown


Japanese market


Assumptions and sources


Compliance rates


Cost of treatment


Market breakdown


Summary






THE FUTURE DECODED


Introduction


Epidemiology forecasts to 2008


Prevalence


Treated population


Pipeline analysis


Xyrem (sodium oxybate)


CEE 03-310


SWOT analysis


Provigil


Xyrem


CNS stimulants


Antidepressants



Market drivers


US forecasts to 2008



Market in 2004



Market in 2008



Summary


European forecasts to 2008


Market in 2004



Market in 2008



Summary


Japanese forecasts to 2008



Market in 2004



Market in 2008



Summary


Summary


APPENDIX


Datamonitor's Central Nervous System Business Unit


Table of tables


Etiology


Epidemiology


Diagnosis, treatment and compliance


Clinical trial data


R&D research methodology


Introduction


Hypothesis formulation


Hypothesis testing


Data verification and quality control


Pricing data


Introduction


Source prices


Ex-manufacturer, wholesaler and retail prices


Data validation and margin calculation


Quality control


Patent data







Ordering: Order Online - visit http://www.researchandmarkets.com/reports/917

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 12/10/2008 11:17:37
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Strategic Perspectives 2001: Narcolepsy - Specific Drugs are Waking up the Market

Web Address:
http://www.researchandmarkets.com/reports/917

Office Code:
OCHKFJPKTWW

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €3,381.00 + EUR€ 50.00 Shipping/Handling *
Electronic €3,424.00
Electronic - Site License €3,317.00

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 12/10/2008 11:17:37


Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World